ATTR

Alnylam’s vutrisiran aces ATTR cardiomyopathy readout
Pharmaphorum
Mon, 06/24/24 - 10:52 am
Alnylam
RNAi
vutrisiran
ATTR
cardiomyopathy
Alnylam changes to heart drug trial spark doubts, sinking shares
BioPharma Dive
Thu, 02/15/24 - 07:13 pm
Alnylam
clinical trials
vutrisiran
ATTR
BridgeBio taps investors for $1.25B to fund showdown with Pfizer
Fierce Biotech
Thu, 01/18/24 - 11:00 am
BridgeBio
Pfizer
funding
ATTR
BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)
Yahoo/GlobeNewswire
Sun, 08/27/23 - 04:28 pm
Bridge Bio
clinical trials
acoramidis
ATTR
ATTR-CM
AstraZeneca adds Latin America to Ionis ATTR partnership for $20M
Fierce Biotech
Fri, 07/28/23 - 11:48 am
AstraZeneca
Ionis Pharmaceuticals
Latin American
eplontersen
ATTR
Ionis, AstraZeneca's polyneuropathy med improved patients' quality of life in phase 3, teeing up battle with Alnylam
Fierce Biotech
Mon, 04/24/23 - 10:26 am
Ionis Pharmaceuticals
AstraZeneca
eplontersen
Alnylam
ATTR
AZ preps FDA filing for $3.6bn amyloidosis drug eplontersen
Pharmaforum
Tue, 06/21/22 - 10:57 am
AstraZeneca
eplontersen
Ionis
ATTR
Alnylam, awaiting key study data, builds case for its next rare disease drug
BioPharma Dive
Sat, 01/22/22 - 02:12 pm
Alnylam
ATTR
vutrisiran
AstraZeneca goes bigger in amyloidosis with Neurimmune deal
Pharmaforum
Fri, 01/7/22 - 10:33 am
AstraZeneca
ATTR
Neurimmune
NI006
Pfizer's new Vyndaqel franchise worth far more than $1.5B, analyst figures
Fierce Pharma
Thu, 05/30/19 - 12:36 pm
Pfizer
tafamdis
ATTR
Vyndaqel
Can Pfizer Leap Over the Competition With This Potential Blockbuster?
Motley Fool
Wed, 05/8/19 - 10:03 am
Pfizer
Vyndamax
tafamidis
ATTR
Alnylam
Onpattro
Akcea Therapeutics
Tegsedi
Eidos Therapeutics
AG10
Insurers Brace For Pfizer's $225K Heart Drug And Whether To Pay For It
Forbes
Mon, 05/6/19 - 07:27 pm
Pfizer
tafamidis
insurers
PBMs
ATTR
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
Xconomy
Mon, 05/6/19 - 10:54 am
FDA
Pfizer
tafamidis
Vyndaqel
Vyndamax
ATTR
Alnylam
Akcea
FDA Accepts Pfizer Submissions for Review of Treatment for Rare Amyloid Related Heart Disease
CP Wire
Mon, 01/14/19 - 10:37 am
Pfizer
ATTR
transthyretin amyloid cardiomyopathy
tafamidis
FDA Accepts Pfizer Submissions for Review of Treatment for Rare Amyloid Related Heart Disease
Mon, 01/14/19 - 10:09 am
Pfizer
ATTR
transthyretin amyloid cardiomyopathy
tafamidis
Eidos Therapeutics raises $106M IPO to advance ATTR med
Fierce Biotech
Wed, 06/20/18 - 03:41 pm
Eidos Therapeutics
IPOs
ATTR
rare disease
With Pfizer's 'pipeline surprise,' there's a new kid on the ATTR block
Fierce Pharma
Sat, 03/31/18 - 09:58 am
Pfizer
ATTR
tafamidis
Alnylam's star RNAi drug keeps the pace on the way to Phase III
Fierce Biotech
Tue, 04/21/15 - 12:20 pm
Alnylam
RNAi
Patisiran
ATTR
Alnylam's Biggest Opportunities
Motley Fool
Wed, 10/2/13 - 10:02 am
Alnylam
RNAi
ATTR
hemophilia
porphyria